To determine whether the efficacy of targeting proliferating F4/80+ macrophages was CD8+ T-cell-dependent, tumor-bearing mice were administered anti-CD8 depleting Abs during the course with or without clodronate liposomes treatment. This evidence concerns the gene CD8A and neoplasm.